Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Connecting Global Economies
Flash News
SpaceX dives 10% after AI spending surge rattles investors
MTV’s The Challenge Couples Status Check: Who Found Love?
Progressives didn’t get the big election night they wanted
Newcastle to sanction £75m sale of Bruno Guimaraes to Arsenal
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
Europe drought threatens energy, shipping and growth
Taylor Swift’s Kansas City Eras Tour Show Shoutout
Post-deadline Giants take stock, along with a deep breath: ‘This is our chance’
Opinion | Do You Know Who Pays if Your AI Agent Goes Rogue?
Novo Nordisk’s raised forecast fails to change the debate over its obesity business
Wednesday, August 05, 2026